Show simple item record

dc.contributor.authorYildiz, Zeynep
dc.contributor.authorKOCAZEYBEK, Bekir Sami
dc.contributor.authorOzbey, Dogukan
dc.contributor.authorPEKPAK, Meltem
dc.contributor.authorATAMAN, Müveddet Rezzan
dc.contributor.authorMURT, Ahmet
dc.contributor.authorALTIPARMAK, MEHMET RIZA
dc.contributor.authorYadigar, Serap
dc.contributor.authorYalin, Serkan Feyyaz
dc.date.accessioned2021-12-10T10:39:32Z
dc.date.available2021-12-10T10:39:32Z
dc.identifier.citationMURT A., ALTIPARMAK M. R. , Yadigar S., Yalin S. F. , Ozbey D., Yildiz Z., KOCAZEYBEK B. S. , PEKPAK M., ATAMAN M. R. , "Antibody responses to the SARS-CoV-2 vaccines in hemodialysis patients: Is inactivated vaccine effective?", THERAPEUTIC APHERESIS AND DIALYSIS, 2021
dc.identifier.issn1744-9979
dc.identifier.othervv_1032021
dc.identifier.otherav_4cffb471-f208-456d-9808-6068d5023c6f
dc.identifier.urihttp://hdl.handle.net/20.500.12627/170338
dc.identifier.urihttps://doi.org/10.1111/1744-9987.13752
dc.description.abstractIntroduction Vaccines generally have reduced effectiveness in hemodialysis patients and a similar condition may also apply for the SARS-CoV-2 vaccines. The aim of this study was to analyze humoral responses of hemodialysis patients to SARS-CoV-2 vaccines. Methods Eighty-five maintenance hemodialysis patients who received either inactivated or mRNA SARS-CoV-2 vaccines were investigated. Antibody levels were measured by a commercial antibody kit, which detected antibodies toward receptor binding domain of the SARS-CoV-2 spike protein. Comparative analyzes were carried between vaccine groups and with a control group of 103 healthy volunteers. Results Seropositivity rate and antibody levels were significantly lower in hemodialysis patients who received inactivated vaccine (p = 0.000). While mRNA vaccine had better immunogenicity, both vaccines protected from symptomatic infection when seropositivity was achieved. Discussion/Conclusion When used in the same dose with the general population, inactivated SARS-CoV-2 vaccines generate reduced humoral response in hemodialysis patients. mRNA vaccines have better immunogenicity in this group.
dc.language.isoeng
dc.subjectTıp
dc.subjectNefroloji
dc.subjectNephrology
dc.subjectUrology
dc.subjectHematology
dc.subjectHealth Sciences
dc.subjectHEMATOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectÜROLOJİ VE NEFROLOJİ
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectHematoloji
dc.titleAntibody responses to the SARS-CoV-2 vaccines in hemodialysis patients: Is inactivated vaccine effective?
dc.typeMakale
dc.relation.journalTHERAPEUTIC APHERESIS AND DIALYSIS
dc.contributor.departmentİstanbul Üniversitesi-Cerrahpaşa , Cerrahpaşa Tıp Fakültesi , Dahili Tıp Bilimleri Bölümü
dc.contributor.firstauthorID2770720


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record